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THE FUTURE OF EPIDEMIOLOGY: A MATTER OF METHODS? 
Shah Ebrahim, Jane Ferrie, George Davey Smith 
 
In our first editorial after taking over responsibility for the content of the IJE in 2001 we illustrated 
some of the successes and failures of epidemiology, and asked the question whether epidemiology 
would progress or decay in the 21st century?1 Embracing new opportunities for aetiological 
understanding provided by the human genome project was one strand of our strategy for making 
the IJE relevant - but viewed through the Geoffrey Rose lens that determinants of disease rates in a 
population and influences on individual susceptibility need not be the same.2 3 We were concerned 
that the ‘big picture’ - health and disease are as much social as biological phenomena – should 
remain in view.  Indeed, the role for genetic discovery seemed to be much more attuned to the 
discovery of mechanisms of disease and resulting pharmacological advances.  We questioned 
methodological developments in modern epidemiology which seemed to lack appetite for engaging 
with the wider range of uses of epidemiology proposed by Jerry Morris in the 1940s and 50s.4 5 6 7 8 9 
10 11 12 13 A formal evaluation of the impact, positive and negative, of the increased methodological 
refinement of epidemiology requested in our 2001 editorial has yet to be submitted to IJE. However, 
in this, the final issue of the journal under our editorship, there are major contributions on causal 
thinking in epidemiology which illuminate what modern epidemiology can and cannot do. 
In 2001, what did we want to do?  Up to that point, papers published in the IJE had very largely 
consisted of original manuscripts reporting new data. We noted that the most important paper the 
journal had published in its lifetime was one of the few that was not of this type: an invited talk at an 
International Epidemiology Association meeting (with few references) beautifully and economically 
summarising Geoffrey Rose’s big idea, alluded to above, with the catchy title ‘Sick individuals and 
sick populations’.2 Widespread understanding and application of previous epidemiological research 
was generally lacking, so in our first issue we published a reprint of a 1943 German case-control 
study on smoking and lung cancer.14 With its accompanying commentaries,15 16 17 18 19 this was the 
first of the ‘Reprints and Reflections’ which were to become an important IJE staple over the next 16 
years. Later in 2001 it was the turn of the Rose paper,20 from only 16 years previously (and with 
rather pleasing symmetry we are now the same distance in time from its reprint). Reflecting on the 
prescience and influence of early contributions to the analysis of genetic influences on human 
phenotypes by Richard Lewontin21 22 or to metabolomic phenotyping by John Moreton,23 as well as 
showing how bright minds came to wrong conclusions about the causes of cholera, peptic ulcer and 
AIDS, can inform future research and act as an immunization against repeating errors. But our 
innovations were not just about history. From the start we expanded to include editorials, 
commentaries, point-counterpoint debates, themed issues, theory and methods, and diversions. 
Over the next 15 years, many other types of article were added: Cohort profiles, Health and 
Demographic Surveillance Systems (HDSS) profiles, Data Resource profiles, Software Application 
profiles, Education Corner, Cochrane Corner, Photo essays, Book reviews, Special issues, and 
Supplements, together with blogs, press releases, and twitter; all brought into being through the 
enthusiasm, critical eye, and hard work of what grew from 15 associate editors in 2001 to become a 
group of 45 editors and 3 editorial staff in 2016. 
The question we posed in 20011 was whether a bright young scientist who wanted to make a 
contribution to population health should build a career in epidemiology or head for the nearest 
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polymerase chain reaction thermal cycler? It is gratifying to see that in many parts of the world 
epidemiology departments have their own genetic, epigenetic and -omics facilities so the question, 
happily, is now moot.  A question that remains of importance is whether the focus on genetic and –
omics epidemiology and new methods of causal inference are freezing out applications of 
epidemiology in health services, public health, and clinical medicine.7   
 
Genes – explaining all or none of it?  
 
Early successes in infectious disease epidemiology were extended in the 20th century with links 
established between tobacco and lung cancer, air pollution and winter deaths, and the identification 
of many cardiovascular disease risk factors, in which epidemiologists were not only involved in 
identifying causes but also in evaluating methods of prevention. Concerned that “big data,” 
phenomenology, and personalised medicine were luring epidemiology away from its traditional 
purposes, Lew Kuller, writing in 2015,24 noted that “epidemiology is now defined as the collection of 
large sample sizes and measurement of numerous variables from stored samples to facilitate 
estimation of disease risk over time”. Although personalised medicine, envisaged by Francis Collins, 
director of US National Institutes of Health, as genetically based, individualised preventive 
medicine,25 has not gained general traction for diagnosis or screening due to the small effects of 
most common genetic variants on the risk of common diseases,26 genetic epidemiology has become 
a core function of most academic departments. It has also laid the path for precision medicine, 
defined by the National Institutes of Health as "an emerging approach for disease treatment and 
prevention that takes into account individual variability in genes, environment, and lifestyle for each 
person."27 Precision (or stratified) medicine, the form now promoted by Collins,28 provides another 
opportunity to capitalize on the massive investments in the human genome project, low-cost whole 
genome sequencing and more recent –omics research.  Precision medicine builds on proof of 
concept studies that have identified specific genotypes among cancer patients and indicate 
biological pathways and treatments. For example, in chronic myeloid leukaemia presence of the 
Philadelphia chromosome somatic anomaly, the BCR-ABL fusion gene produces an abnormal 
tyrosine kinase protein, and a kinase-inhibitor was found that improved survival dramatically.29 This 
relatively old example remains a “pin-up” case, but slowly others have emerged. For common 
diseases, however, the situation is less clear. For example, results from observational studies, which 
supported using genotypes to guide anticoagulation treatment,30 31 were not confirmed in three 
large randomized trials that found genotype-informed algorithms no better than a clinical algorithm 
in guiding initiation of warfarin treatment.32 Balancing the power of large scale studies to produce 
reliable data applicable to groups against the common-sense notion that individuals should be 
treated according to their very specific characteristics remains, after nearly two centuries, the 
central conundrum of “evidence based medicine”,33 and was the focus of another of our historical 
reprints.34 35 36 37 38 
 
A decade of Mendelian Randomization 
While the clinical enterprise of precision (or stratified) medicine may gain traction over the next 
decade, using genetic variants to explore environmentally modifiable (rather than genetic) causal 
pathways - Mendelian randomization – has, slowly, emerged as a successful approach to harnessing 
new knowledge gained from the human genome project. Since our original expositions on 
Mendelian randomization,39 40 numerous methodological advances have been made. These range 
from multiple demonstrations of the plausibility of the basic concept that genetic variants (which 
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can proxy for a potentially modifiable exposure) are essentially unrelated to confounding factors,41 
to the extension of Mendelian randomization into the hypothesis-free resolution of causal directions 
in correlated networks.42 43 This extensive methodological development has been undertaken in 
response to the challenges of new substantive applied questions and increasingly detailed genetic 
data and has enabled (and continues to enable) more sophisticated questions to be answered using 
the framework of Mendelian randomization. 
 
Mendelian randomization has provided definitive answers to both public health and clinical practice 
questions.  For decades public health has struggled with defining whether moderate alcohol 
consumption is beneficial or harmful for cardiovascular disease.  In observational studies, people 
drinking light-to-moderate amounts of alcohol experienced lower rates of cardiovascular disease44 
and had lower levels of many cardiovascular risk factors than non-drinkers or heavy drinkers45 46 47 48 
49 – sometimes termed a ‘J’- or ‘U’-shaped association. There was also evidence that all-cause 
mortality is lower among men drinking 34 units/week or less and women drinking 16 units/week or 
less.50 These non-linear associations have confused alcohol public health policy, as a ‘safe’ level of 
drinking for cardiovascular health is consistent with moderate consumption, a level of consumption 
potentially hazardous for other health outcomes.  In a review first published in the IJE in 1984 and 
reprinted in 2001 that reported that moderate drinkers from diverse populations have a lower CHD 
risk than abstainers, Michael Marmot postulated that abstainers were likely to differ from moderate 
drinkers in a number of ways.51 In addition to confounding, such associations are also potentially 
unreliable because of reverse causation (sick people are told to stop drinking) – situations in which 
Mendelian randomisation can provide alternative means of examining associations. The Alcohol-
ADH1B consortium has conducted Mendelian randomization analyses showing that people carrying 
the rs1229984 A-allele of the ADH1B gene (a genetic variant associated with lower levels of regular 
alcohol consumption and a lower risk of alcohol dependence) have a more favourable cardiovascular 
profile and a reduced risk of coronary heart disease. The researchers concluded “reduction of 
alcohol consumption, even for light to moderate drinkers, is beneficial for cardiovascular health”.52 A 
development of standard Mendelian randomization analysis, testing for non-linear causal effects, 
found no strong evidence of U-shaped associations between alcohol consumption and 
cardiovascular risk factors.53 This, and other new evidence appears to have influenced alcohol 
guidance in the UK to promote lower levels of consumption.54 In a similar fashion high-profile 
epidemiological publications suggested that moderate alcohol consumption among pregnant 
women was associated with optimal offspring outcomes, superior to those of non-drinking or more 
heavily drinking mothers.55 Comparison of behavioural and socioeconomic measures by drinking 
category for women in the study confirmed Marmot’s hypothesis that abstainers were indeed very 
different to those who were light drinkers in pregnancy,(Figure 1) and a paper in the IJE which 
applied Mendelian randomization to the question reached the conclusion that any alcohol 
consumption was detrimental,56 a position now recapitulated in UK guidelines.(Box 1) 
 




Figure 1. Comparison of behavioural and socioeconomic measures by drinking category, women. 
Figure based on data provided in reference 55. 
 
In clinical medicine, Mendelian randomization has contributed to evaluating pharmacological 
strategies for preventing cardiovascular disease.  For example, raised circulating C-reactive protein 
(CRP) is strongly associated with cardiovascular disease (CVD) and with recurrence of CVD events, 
suggesting that searching for drugs that lower CRP could provide new means of prevention.57 
Mendelian randomization studies have now shown convincingly that CRP is not causally related to 
cardiovascular disease,58 thereby avoiding the cost and time of a likely futile evaluation of anti-CRP 
drugs.  
 
The first cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, raised HDL-cholesterol but 
also, unexpectedly, increased blood pressure and cardiovascular events.59 A Mendelian 
randomization study was conducted in which associations between variants in the CETP gene, lipid 
levels and blood pressure were compared with the pharmacological effects.  The CETP gene variant 
that mimicked the torceptrapib effect on lipids, but did not raise blood pressure, indicated that the 
drug caused an off-target effect, so searching for other CETP inhibitors without such off-target 
effects would be worthwhile.60 However, Mendelian randomization studies indicate that genetic 
variants that raise HDL cholesterol are not associated with lower risk of cardiovascular disease,61 
predictions borne out by clinical trials of CETP inhibitors mounted by Eli Lilly, Roche, and Pfizer.62 
Merck has continued to support its trial, expected to report in 2017,63 of a CETP inhibiting agent that 
produces a more substantial LDL cholesterol lowering effect than other such agents. However no 
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company would, in the post-Mendelian randomization age, develop a drug solely based on its HDL 
cholesterol raising effects. 
 
Statins increase the risk of type 2 diabetes, which may be a specific effect of inhibition of HMG-
coenzyme A reductase (HMGCR).64 Trials of a new class of cholesterol lowering drug, proprotein 
convertase subtilisin-kexin type 9 (PCSK9) inhibitors,65 anticipated not to increase diabetes, are 
underway, however Mendelian randomization suggests that the relative effects on cardiovascular 
events and diabetes are similar for both PCSK9 and HMGCR.66  The pharmaceutical industry will 
increasingly undertake Mendelian randomization studies to improve discovery of suitable targets for 
development which will reduce the huge financial losses due to failed phase 3 trials.67  
 
 
Saved from irrelevance by new methodologies? 
Representativeness and collider bias  
The National Institutes of Health’s Precision Medicine Initiative Cohort, slated to enrol a million 
adults, will recruit a highly non-representative subset of the population – essentially volunteers. As it 
is often claimed that examining genotype and disease phenotype associations should be robust to 
any selection biases, does this matter? A recent study, which found that women and children at 
higher genetic risk for schizophrenia and related phenotypes were less likely to participate in a large 
longitudinal study, suggested that such non-participation might introduce such biases.68 In a point-
counterpoint in this journal, Ken Rothman and colleagues argued that representativeness should be 
avoided on the grounds that scientific inference benefits from having tightly defined, highly 
compliant participants.69 Although they concede that representativeness is required for the practical 
goal of applying knowledge to populations, they also claim: “Surveys of opinions, of the prevalence of 
disease, of habits or of environmental exposures may be informative, but they are not science in the 
same way that causal studies about how nature operates are science”. The elevation of causal 
studies as the science of epidemiology is debated extensively in this issue of the IJE. Commentaries 
on Rothman and colleagues paper were broadly supportive, although an extensive independent 
review of this issue was critical of their position.70 Richiardi and colleagues in their commentary drew 
a distinction between intentional (e.g. studying smoking in British doctors to reduce potential 
confounding by life-style factors) and unintentional non-representativeness (e.g. low response rates 
in recruiting to cohort studies), but considered them to be broadly equivalent in terms of threats to 
validity of a study.71 They argued that the exposure-outcome association might be biased if the 
exposure of interest and another risk factor for the disease were associated with the probability of 
inclusion – that is, collider bias72 – but presented reassuring evidence from Monte Carlo simulations 
and an empirical study that the size of such bias would likely be small. 71  
 
In order to avoid the situation where commentaries on Rothman and colleagues’ point-counterpoint 
article became a one-sided love-in, the editors were forced to give examples of where non-
representativeness is an important cause of bias in exposure-outcome associations.73 In a rebuttal, 
Rothman and colleagues suggested that we were misguided to assume that a well-designed and 
conducted randomised clinical trial (RCT) gave the right answer.74  
It is likely that analyses using large scale biobank resources comprised of volunteer participants (e.g. 
UK Biobank recruited about 5% of those invited) will generate many spurious findings. Confounding 
of the exposure of interest with lifestyle or socioeconomic factors, and reverse causation, whereby 
disease status influences exposure rather than vice versa, may invalidate causal interpretations of 
observed associations. Using data from the British Women’s Heart & Health Study we examined 
4560 pairwise correlations of non-genetic variables. Of these, at the 1% significance level 46 would 
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be expected to be associated by chance. However, we found associations between 2,036 (45%) of 
them to be “statistically significant” (not a term of which we approve75) giving an observed to 
expected ratio of 44, p for difference O:E < 0.000001).41  The associations we detected included that 
HRT apparently “protected” against CHD,76 that vitamin C “protected” against CHD,77 78 and that 
vitamin E “protected” against CHD. Although we did not publish the latter association, we did use 
the “protective effect” of HRT and vitamin C on CHD to illustrate the problems of observational 
epidemiology. Indeed many of the findings from other large-scale observational studies, such as the 
Health Professionals Follow-up Study, Physicians Health Study and Nurses’ Health Study cohorts79 80 
81 82 83 have not had their findings confirmed in large RCTs when these have been conducted. 
Biobanks even larger in scale than the Harvard studies have yet greater possibilities for generating 
spurious findings to fill medical journals and newspapers.  
An important distinction in this discussion of representativeness is the potential clear-cut effects of 
selection into a target population, the response rates in a study based on that target population, and 
attrition rates among the responders (in long-term cohort studies). Selection into a target population 
was discussed in a short 1911 article by Arthur Pigou, reprinted in this issue, ‘Alcoholism and 
Heredity’, on the relationship between parental alcoholism and adverse offspring development. 
Pigou’s critique targeted high-profile studies led by Karl Pearson that utilised data from particular 
deprived geographical regions. He argued that comparisons between the offspring of alcoholic and 
non-alcoholic parents would be biased: the former were better off as they were able to pay rent and 
buy alcohol, whereas the latter only had to be able to pay rent, but both found themselves in the 
same miserable target areas.84 Simulation studies indicate that even modest influences on selection 
into or attrition from a study can generate biased and potentially misleading estimates of both 
phenotypic and genotypic associations.85  
 
Traits that are entirely unrelated in the general population may appear to be correlated in selected 
samples, if both traits influence selection, as a result of collider bias. Genetic variants are, in general, 
unrelated to confounders. When many variants are combined into polygenic scores that are 
associated with a phenotype, an association between the phenotype and participation will allow the 
score to be more strongly related to participation than is each individual variant. This, in turn, can 
potentially lead to bias. Studies using polygenic scores, genome-wide allelic scores,86 and whole-
genome genetic correlations (including Linkage Disequlibrium regression)87 88 in highly selected 
samples are most at risk of producing biased and potentially misleading results. 
 
A recent toy example using UK Biobank data showed how a biologically spurious association 
between SNPs associated with height (B) and sex (A) could be achieved by adjusting for height which 
acts as a collider (see Figure 2).89 More studies illustrating this problem are in the pipeline.90 91 
Further caveats arise in studies where common genetic variants associated with the condition of 
interest, e.g. schizophrenia, are also associated with non-participation, non-completion of 
questionnaires and non-attendance at data collection throughout childhood and adolescence. 68 
Analyses of schizophrenia-related phenotypes as outcomes may be biased by the non-random 
missingness of these phenotypes in the study population – for example, an implausible inverse 
association between the polygenic score for schizophrenia and reported psychosis-like symptoms is 
seen among the respondents.92   
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Figure 2. A biologically spurious association between SNPs associated with height (B) and sex (A) can 












Causal inference and DAGs 
Despite eloquent presentations of the purpose and uses of epidemiology over the last century,5 93 94 
concerns about its direction have been voiced repeatedly.2 7 95 96 97 98   Earlier discourses highlighted 
the role of epidemiology in improving public health and providing a scientific basis for clinical 
practice.  Much debate now centres on the over-emphasis on identifying causes of disease as the 
sole purpose of ‘modern epidemiology’, and with an obsession with ever more complex statistical 
methodology. In this issue we have brought together articles written by some of the more influential 
epidemiologists involved in advancing causal methodology and a series of critical commentaries to 
develop and further the debate about the uses of epidemiology.99 100 101 102 103 104 105 106 107 108 109 110 
111  
 
Arguments for and against modern ideas about causal inference revolve around the ways in which 
causes should be defined.  The potential outcomes approach (related to counterfactual thinking) can 
be seen as too rigid and too far removed from many of the complex ‘dirty’ problems (e.g. social 
inequalities, racism, ecological changes) of social epidemiology. If a potential ‘cause’ cannot be 
manipulated is it sensible to disregard it, relegating it to the ‘not suitable for epidemiology’ 
category? The use of directed acyclic graphs (DAGs) may, if properly constructed, aid causal thinking 
and help plan relevant analyses.112 But DAGs and analyses may increasingly be constructed by 
computer programs without sufficient application of biological/pathological knowledge and it is not 
clear whether the resulting DAGs aid analysis or drive them, or whether they constrain what can be 








height raising alleles 
Positive correlation, 








Figure 3.  A DAGitty diagram to explore associations of BMI and physical activity with atopy.113 
Licensed under CC BY 4.0. 
 
The authors responsible for Figure 3 conclude “BMI and physical activity in early childhood are 
associated with atopic sensitization, atopic dermatitis and asthma in later childhood”.113  However, 
the DAG does not provide a comprehensive picture. For example, it does not include paternal 
factors,114 ethnicity,115 respiratory infections,116 socio-economic position,117 or distinguish different 
atopy phenotypes.118 DAGs, however elegant and expansive, are unlikely to improve causal inference 
without prior knowledge and, ultimately, need the causal anchors - proposed by Sewall Wright in his 
work on path analysis in the 1920s – to make quantitative causal interpretations.119  The massive and 
still growing knowledge available on the causal effects of germline genetic variants on phenotypes 
provide such anchors and will enable better exploitation of observational data using Mendelian 
randomization approaches to causal inference.  Investigators using the machine algorithms now built 
into DAG programs should heed Siddhartha Mukherjee’s warning: “The medical revolution will not 
be algorithmized".120  
Does a more pluralistic approach – e.g. inference to the best explanation101 - to identifying causes 
help more?  How will new proposals to develop a more formal approach to triangulation of findings, 
defined as “the practice of strengthening causal inference by integrating results from several 
different approaches, where each approach has different (and assumed to be largely unrelated) key 
sources of potential bias”121 contribute to how we carry out epidemiology in the future? 
 
Population health sciences: epidemiology in smarter clothes? 
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Population health sciences is a growing field, popular with graduate students and doctoral aspirants, 
defined as “the study of the conditions that shape distributions of health within and across 
populations, and of the mechanisms through which these conditions manifest in the health of 
individuals”.122  This quotation is taken from a primer, by Katherine Keyes and Sandro Galea, for 
students of this new discipline. Keyes and Galea’s primer is dedicated to Geoffrey Rose’s 
aforementioned seminal work on prevention, in which he articulated the importance of two 
premises: a) distinguishing the causes of susceptibility from the causes of incidence – sick individuals 
and sick populations; and b) that shifting the population distribution of adverse exposures 
downwards will prevent more disease than focusing on those at the top end (high risk) of the 
distribution.2  Their definition of population health science clearly overlaps with most definitions of 
epidemiology – e.g. the study of the distribution and determinants of health-related states or events 
(including disease), and the application of this study to the control of diseases and other health 
problems”.123   
 
Is there a need for this new discipline? The rarefied environment of modern epidemiology has, in 
some schools of public health, focused so much on causal inference using counterfactual reasoning 
and on ever more complex statistical methods that there is little room for working across disciplines 
– anthropology, biology, demography, economics, genetics, medicine, politics, public health, 
psychology, sociology, etc. – and working on problems of importance - ageing, climate change, 
conflict, development, emergent infections and pandemics, equity, health and social care, global 
health, etc. In their short primer Keyes and Galea promote exciting ideas and practical ways of 
integrating methods drawn from different disciplines to tackle problems of consequence.  This issue 
of the IJE brings together articles on causal inference, identifies the common ground between 
epidemiologists who appear to have taken polar positions, and, we believe like Keyes and Galea’s 
primer, will be useful for building theory and practice in epidemiology.   
The need for research cutting across disciplines is exemplified by a systematic review of studies 
evaluating the long-term economic impacts of the deworming children in poor countries (see Re-
analysis, re-appraisal and re-interpretation of data below). Reviewing the research from 
epidemiologic and public health perspectives, rather than solely from an economic viewpoint, 
results in rather different conclusions.  Supporting population health science initiatives in 
departments of epidemiology may be part of the solution to achieving relevance and traction on our 
current (and growing) health problems.   
 
Big data  
Big data can be defined in terms of size, complexity, manipulability and management,124 and in the 
context of health sciences ranges from electronic patient records125 to open access genetic and 
phenotypic datasets. In the latter category, UK Biobank is the current front-runner, and has become 
an extremely valuable resource. However, ease of access requires a careful approach to data 
analysis and interpretation if spurious findings due to selection bias, confounding, or just straight-
forward data torture are to be avoided. An important step in improving causal inferences will be for 
investigators to publish their analytic code along with their paper to enable replication and 
additional analyses to be conducted. Other sources of big data also have their advantages and 
drawbacks. Big data derived from hospital episode statistics and from routine contacts in primary 
care are widely used to explore health care delivery, effectiveness and variation in outcomes. For 
example, the Clinical Practice Research Datalink (CPRD) provides an ongoing primary care database 
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of anonymised medical records from general practitioners, with coverage of over 11.3 million 
patients from 674 practices in the UK.126 This database was used to examine the association 
between measles, mumps and rubella (MMR) vaccine and autism and successfully debunked the 
idea that MMR caused autism.127  In England a large scale health policy change – “the 7-day NHS” - 
was initiated on the basis of an analysis of hospital episode statistics (14.8 million hospital 
admissions) that showed excess mortality at weekends.128 The investigators refused to share their 
analytic code on grounds of research governance,129 thus prohibiting other investigators from 
exploring the robustness of their findings using sensitivity analyses and other approaches.  It is only a 
matter of time before all research papers will share their analytic code for the common good.130 The 
extra effort involved in providing sharable analytic code should be seen as time well-spent and 
would avoid the issues that arise when analytic code is lost for future interrogation.131 132  
 
Re-analysis, re-appraisal and re-interpretation of data 
In low and middle income countries (LMICs) issues of analysis and interpretation of data can have far 
reaching consequences. Deworming – mass medication of children and women of child-bearing age 
in LMICs – is a massive initiative involving the World Health Organisation and the ‘Deworm the 
World’ campaign.133  The rationale is simple – a 6-monthly pill will improve nutritional status, 
cognition and school attendance and thereby promote economic development. The underpinning 
evidence includes an analysis by Edward Miguel and Michael Kremer of a study conducted in Kenya 
in 1998-99,134 augmented by data from a study from 1910,135 and an unpublished report of a follow 
up of the original Kenya study.136 The original data and analytic code were made available by Miguel 
and Kremer, and an independent team of investigators undertook a replication and re-analysis, 
which was published in the IJE in 2015.137 138 The re-analyses found a small effect of deworming on 
school attendance but no clear effect on examination performance.139 Perhaps the major triumph 
here is not so much the findings themselves but that the data and code were made available for 
independent scrutiny – an approach that is both inexpensive and quick compared with mounting 
new trials.140   
 
An updated Cochrane review of randomized controlled trials of deworming, found no strong 
evidence of benefits for nutritional status, haemoglobin levels, school attendance or exam 
performance,141 and a mega-trial of two million children in India failed to demonstrate benefits from 
deworming on mortality or weight gain.142  A further piece of evidence is a review by Sophie Jullien 
and colleagues of the unpublished economic studies evaluating the long-term health, schooling and 
economic development effects of the original trials in Kenya and Uganda143 published in this issue of 
the IJE. Disseminated online as working papers without formal peer review and publication, two of 
the three papers have gone through multiple iterations. Nonetheless they are widely cited as 
claiming benefits for health and economic development by advocates of deworming. However, 
according to Jullien and colleagues, they do not appear to stand up to an epidemiological and 
systematic review approach, and the authors conclude: “In the context of reliable epidemiological 
methods, all three studies are at risk of substantial methodological bias. They therefore help in 
generating hypotheses, but should not be considered reliable evidence of effects.” 
 
Are down-stream benefits, such as economic development, feasible in light of no clear benefits for 
up-stream outcomes?144  Despite the growing evidence showing that deworming has little to offer at 
a population level it remains popular with the World Health Organisation145  and the ‘Effective 
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Altruism’ movement, who have claimed deworming is more effective than providing textbooks or 
teachers in Kenya.146  A so-called ‘worm wars’ for and against continuing current deworming policy 
in light of this new evidence has been declared, with considerable media coverage.147  The 
commentators comprise the authors of the original working papers,134,135,136  GiveWell – an 
organisation that assesses evidence on interventions supported by charities, and other scientists 
with methodological interests.  Not surprisingly, there are points of difference and of emphasis 
about the analyses by Jullien and colleagues, many of which are covered in the 8 commentaries on 
their review.148 149 150 151 152 153 154 155 However, there is some agreement that the evidence base for 
deworming is sparse and further evaluations of its long-term developmental and economic effects 
would be helpful.   
 
The next 16 years. Where is (publishing) epidemiology going? 
Missing the obvious: social inequalities in health 
The 1980s were the decade when social inequalities became a major preoccupation with 
epidemiologists. Commissioned in the UK under a Labour administration, the Black Report156 on 
social inequalities in health was published by the newly elected conservative Thatcher government 
on a national holiday in August 1980 in the hope it would be ignored. Instead it became an 
inspiration for a generation of epidemiologists and social 
scientists around the world and social inequalities were 
described for almost every measure of health and disease 
across countries rich and poor. However, tackling social 
inequalities in health from the epidemiological viewpoint 
proved difficult. Interventions, such as CVD prevention 
programmes that are focused on individual behaviour 
change, were differentially taken up by more advantaged 
groups in the population, thereby exacerbating social 
inequalities.157 158 More recently the social inequalities 
theme has rather run out of steam, despite valiant efforts 
by Michael Marmot and colleagues to keep it high up 
research and policy agendas worldwide.159 160 161 This 
wane in interest has been attributed by some to the 
increasing interest in genetics and by others to the 
obvious lack of impact on the underlying drivers of 
inequality – Figure 4. Indeed describing trends in terms of 
absolute and relative changes in risk by socio-economic 
position have further confused the question of whether 
outcomes are getting worse or better for the 
disadvantaged in any country.  Taking Britain as a case 
study, the absolute rates of decline in CHD in women under 75 show a marked decline across all 
social class groups (Figure 5).162  
 
Figure 4 – Relation between incomes 
and death rates from Poverty and Public 
Health by GCM M’Gonigle and J Kirby, 





Figure 5. Age-standardised coronary heart disease mortality rates per 100,000, 1994-2008 by 
quintile of deprivation. Great Britain - women younger than 75 years. Reproduced with permission 





Figure 6. Coronary heart disease mortality rate ratios (least deprived quintile as baseline), 1994 to 
2008 by quintile of deprivation. Great Britain – women younger than 75 years. Reproduced with 
permission from BMJ Publishing Group Ltd. 
By contrast, when the relative rates of decline are examined (Figure 6) it is clear that the more 
disadvantaged sections of the population have actually been doing worse over the last two decades. 
Progress or not?  It seems the social inequalities stream of research and activism (in which many 
epidemiologists, to their credit, played a role) could not withstand the much stronger political and 
commercial forces that have dominated public policy in most countries over the last two decades. 
With a newly appointed regressive government in USA, and with India, Russia, and much of Europe 
and Latin America following policies that will not support disadvantaged groups, a resurgence of the 
social inequality agenda will emerge following the patterns of death and destruction that ensue. A 
complementary strategy for the present is to ask questions such as that posed by Oxford 
Geographer Danny Dorling: Can we afford the rich?,163 in order to develop a better understanding of 
how those in power maintain their grip on society.164  There is a role for epidemiology here and it 
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goes beyond description to identifying with greater precision which interventions – political, social 
and health care – have an impact on health and development, and in which contexts. Counterfactual 
methods focusing on identifying intervention effects might help drive a new wave of social 
epidemiology focused on reducing social inequalities in health,165 but care must be taken to ensure 
that proposals as to what can be done are not constrained by what are considered to be acceptable 
questions.  
 
Monitoring and surveillance: back to basics 
Monitoring and surveillance using epidemiological data are fundamental for assessing the health of 
populations, but compared with the tantalising prospect of ‘discovery’ research offered by the 
unravelling of the human genome, epigenetics and –omics technologies they have become areas of 
non-interest. Dorling lamented this phenomenon at a recent meeting 
(http://www.ijeconference.com/live-stream/) when he asked why epidemiologists were not 
interested in the 9% increase in deaths that occurred in Scotland in 2015 and the stagnation of life 
expectancy there for the first time in 160 years (see Figure 7).   
 
Figure 7. Numbers of deaths per year, 2004-2015 Scotland. Reproduced with permission from Danny 
Dorling.166 
The Global Burden of Disease (GBD) project started over 25 years ago. In the absence of robust 
mortality statistics from most LMICs, it attempts to provide much needed information about 
patterns of disease and risk factors by geographic region and over time.  The complex methods used 
to derive GBD estimates make them opaque and difficult to verify.  For example, estimates of Indian 
trends in blood cholesterol and blood glucose between 1980 and 2008 were not based on nationally 
representative data but relied on regional studies conducted between 1994 – 2006 (cholesterol) and 
1989 – 2007 (glucose).167 Statistical models filled in the gaps by ‘borrowing’ from other countries in 
the South Asia region, modelling estimates using income, urbanisation and multiple food type 
availability.168 169  
Excluded from the 2013 analyses, previous GBD reports had included cause-specific mortality data 
from some INDEPTH HDSS sites. This provided an opportunity to make a direct comparison between 
GBD estimates of cause specific mortality and “real world” estimates from verbal autopsy data from 
the INDEPTH field sites. Overall concordance between the two data sources over 50 causes of death, 
two age groups, and three periods was 0·585 (p<0·0001), increasing to 0·770 (p<0·0001) when six 
major cause categories were used (see Figure 8).170 Many countries in Africa and Asia are not able to 
ascertain cause-specific mortality routinely using surveillance methods so GBD estimates provide the 
only information to guide policy.  Continued investment in and creation of more INDEPTH HDSS sites 
are essential for providing real country-specific data and to generate data on risk factors and provide 
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community ‘laboratories’ in which interventions and health system programmes can be evaluated 

























Figure 8. Concordance correlation between GBD and INDEPTH cause-specific mortality findings in 
13 low-income and middle-income countries by six major cause of death categories.  Each point 
represents one country, cause category, age group and 5 year period. The diagonal black line represents equivalence. 
Circles with solid outlines =>15 years of age. Circles with no outline =<15 years of age. Reproduced with permission 
fromLancet Global Health.170 
 
Much was written in 2015 about the notable successes and failures of the Millennium Development 
Goals (MDGs). In an early editorial on the subject in the IJE, Alan Lopez, lamented the omission of a 
measure of health inequalities in the MDGs and the lack of focus on non-communicable disease as 
missed opportunities.172 Secretary General of the United Nations (UN), Dr Margaret Chan, described 
2015 as a time for global action. ‘During this single year we have the unequivocal opportunity and 
responsibility to adopt sustainable development, to restructure the global financial system in line 
with our needs, and to respond finally and urgently to the challenge of human-induced climate 
change.’173 Sadly, in common with tackling social inequalities in health, global action on the 
Secretary General’s aspirations fell woefully short. Nonetheless in September 2015 the UN General 
Assembly established the Sustainable Development Goals (SDGs); 17 universal goals, 169 targets, 
and 230 indicators leading up to 2030. GBD collaborators used indicators from the GBD study in 
2015 to set the baseline for the 33 health-related SDG indicators and examine progress on these 
between 2000 and 2015. Although some overall progress was documented, as might be expected, 
greatest progress was seen for the MDG-related indicators.174 Despite this, the authors observe that 
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gains on the health-related MDG indicators will need to be sustained and, in many cases, accelerated 
if the ambitious SDG targets are to be achieved.  
 
Global health: equitable authorship 
Submissions to the IJE from LMIC authors made up only 19% of the total in 2015; a figure that has 
changed little over the last decade.  Each year, we have received papers from high income country 
(HIC) authors using data derived from LMICs that include no authors from the relevant countries. 
Presumably the investigators believed that no-one deserved authorship even though it is hard to 
understand how the data were obtained without the involvement of LMIC researchers.  A variation 
we observed was token authorship for investigators from LMICs in the middle of the author list – the 
‘thinly filled LMIC sandwich’ approach to authorship; problems identified in previous issues of the 
journal.175 176  
 
In this issue of the IJE we publish one of the first studies to explore lead authorship for researchers in 
LMICs.  Using randomised controlled trials of interventions for major infectious diseases (i.e. 
HIV/AIDS, malaria, and tuberculosis) conducted in LMICs as indicator articles, Margaret Kelaher and 
colleagues demonstrated a 5-fold increase in numbers of articles in the post-MDG (2000-2012) 
period than in the 10 years before. However, proportionally the increase was 3-fold greater for HIC 
first-authorship compared to LMIC first-authorship. LMIC first authorship increased over time for 
research funded from LMICs, but declined for research funded by US and non-US HIC sources.177 
These data suggest that the Global Health movement currently benefits HIC institutions and 
investigators at the expense of LMIC researchers – surely an unacceptable form of neo-colonialism?   
 
Is publishing epidemiology going to continue? 
Most epidemiological studies are not published in epidemiology journals, generally because 
epidemiology journals have lower impact factors than general medical and speciality journals.  
Furthermore, epidemiological studies often gain wide public attention, especially when they concern 
the effects of lifestyles on health which provide tantalizing media tweets, help sell newspapers, 
promote the journals in which they are published, and fulfil funders’ requirement for dissemination. 
Unfortunately, many of these studies massage tiny relative risks into major hazards to health, or 
produce public confusion by reporting contradictory findings. Anything with sex in the title is a 
winner; a 2015 paper by Niklas Långström and colleagues on sexual offending,178 not only resulted in 
extensive media coverage, but also over 57,000 downloads of the original paper. Ticking so many 
boxes it seems likely this stream of epidemiology will continue for the next 16 years. 
The opportunities for web-publication of findings, independent of commercial or profit-for-purpose 
publishers, have been taken up by several scientific disciplines (e.g. physics, astronomy).  In medical 
and related disciplines publication in print and/or on-line journals remains the main route for 
dissemination and discussion of findings, and it seems unlikely that these journals will simply 
disappear.  Richard Smith, former editor of the BMJ, tells a story about his early experiences of being 
an editor. The editors of a medical society journal, published by BMJ Publications, asked ‘What is the 
added value of the publisher for the academic community? We get grants, do the research and write 
the papers; we do the peer review, decide which papers to publish, obtain commentaries and 
editorials, and deal with letters, appeals and complaints.  All of this is at no cost to the publisher but 
you take a large share of the profits generated by advertising and library subscriptions.’  It is this last 
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issue that explains why medical journals stay in business and medical societies are better off with 
publishers – the profits that publishers make are shared with the medical societies and provide a 
major source of income.  In the case of the International Epidemiology Association (IEA), the IJE 
provides 80% of its annual income and without the IJE, the IEA would cease to exist.  
In our first editorial in 2001 we applauded the BioMed Central initiative and have since been 
impressed by the growth of PLoS journals, which attempt to contextualize articles and have 
managed to engage with many prominent researchers.  However, we did not foresee the 
requirements by major research funders for articles to be open access on publication or the massive 
growth of online-only medical journals. The latter are now making it very difficult to discern which 
journals are legitimate and which are predatory – that is, established simply to make money and 
have none or very little editorial oversight or input, or appear to be compiled by machines (see 
Figure 9).179 180  In collaboration with Oxford University Press (OUP), which publishes the IJE, we had 
planned to launch an online only journal – IJE Open – to provide a forum for descriptive studies from 
LMICs and have a strong focus on population health. Unfortunately, these plans did not withstand 
changes of management within OUP and IEA. 
A solution to sifting the digestible from the garbage has recently been provided by the Wellcome 
Trust, a major UK biomedical research funder. The ‘Wellcome Open Research’ initiative181 aims to 
remove the science funded by the Trust from the grasp of publishers and onto its own online 
platform, which uses services developed by the F1000 Research platform.182  Following a basic check 
by the in-house editorial team, manuscripts are uploaded to the platform with all processing charges 
covered by the Wellcome Trust. Open peer review is conducted after publication and posted with 
the manuscript. There is no rejection or acceptance process, authors select their own reviewers and 
can comment and/or revise their manuscripts in response to the reviews, which are also posted with 
the paper. Wellcome funded researchers are not obliged to use Wellcome Open and can still choose 
to publish papers in traditional journals. Although Wellcome’s purpose is to ensure that all findings 
are in the public domain and not just those that provide strong evidence of association, it is up to 
Wellcome grantees to decide which results they think are worth sharing using Wellcome Open. A 
major advance is that underlying data/code will be available to those who wish to reuse it. Other 
major national and international funders are likely to follow suit, making it quicker for findings to be 
disseminated, and easier for the end user to find quality research at no direct cost. BioRxiv 
(http://biorxiv.org/) is an earlier initiative providing a pre-print server for life sciences run by Cold 
Spring Harbour Laboratory. It has grown dramatically from 5 pages of articles in January 2014 to 67 
pages in December 2016.  This allows investigators to submit their work, which is then citable, prior 
to publication in traditional journals. There is no peer-review, editing or formatting of articles, but all 
are checked for offensive and/or non-scientific content and plagiarism. The Medical Research 
Council in the UK has recently agreed that articles uploaded to bioRxiv can be cited in grants, reports 
and curriculum vitae. 
Time to call it a day 
Although we never had the nerve (despite the occasional need) to follow Hunter S. Thompson’s 
editorial approach at Rolling Stone magazine: “What kind of lame, half-mad bullshit are you trying to 
sneak over on us? Do you take us for a gang of brainless lizards? Rich hoodlums? Dilettante thugs? 
…. Get your worthless ass out of the piazza and back to the typewriter. Your type are a dime a dozen 
around here…”183 (and this to the distinguished author Anthony Burgess); overwhelmingly, editing 
the IJE has been intellectually stimulating and enormous fun. Of course we regret the IEA’s decision 
to cut our funding to the point where it was no longer viable for us to continue. Nonetheless, we 
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wish the new editorial team under Stephen Leeder all the best in their editorial endeavours to ‘un-
fuck the system’ (Figure 9). We would also like to take this opportunity to thank our authors and 
commentators, the members of our editorial board and editorial staff for their unstinting dedication 
and support – it’s been a great ride, but it is time for us to stop, in the words of Philip Larkin, “going 
down the long slide to happiness, endlessly” (Box 2). We are no longer young, and don’t deserve 
such. 
            Box 2 - High Windows by Philip Larkin 
   
When I see a couple of kids 
And guess he’s fucking her and she’s    
Taking pills or wearing a diaphragm,    
I know this is paradise 
 
Everyone old has dreamed of all their lives—    
Bonds and gestures pushed to one side 
Like an outdated combine harvester, 
And everyone young going down the long slide 
 
To happiness, endlessly. I wonder if    
Anyone looked at me, forty years back,    
And thought, That’ll be the life; 
No God any more, or sweating in the dark 
 
About hell and that, or having to hide    
What you think of the priest. He 
And his lot will all go down the long slide    
Like free bloody birds. And immediately 
 
Rather than words comes the thought of high windows:    
The sun-comprehending glass, 
And beyond it, the deep blue air, that shows 
Nothing, and is nowhere, and is endless. 
 
Philip Larkin, "High Windows" from Collected Poems. 
Copyright © Estate of Philip Larkin.  Reprinted by 








Figure 9.  Left Panel – an article that was actually submitted to an online journal, International 
Journal of Advanced Computer Technology, and was reviewed as ‘excellent’.…180 Right Panel – 
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